The Experts below are selected from a list of 19521 Experts worldwide ranked by ideXlab platform

Jorge D Brioni - One of the best experts on this subject based on the ideXlab platform.

  • discovery of histamine h3 antagonists for the treatment of Cognitive Disorders and alzheimer s disease
    Journal of Pharmacology and Experimental Therapeutics, 2011
    Co-Authors: Jorge D Brioni, Timothy A Esbenshade, Tiffany Runyan Garrison, Scott R Bitner, Marlon D Cowart
    Abstract:

    H 3 antagonists increase the release of brain histamine, acetylcholine, noradrenaline, and dopamine, neurotransmitters that are known to modulate Cognitive processes. The ability to release brain histamine supports the effect on attention and vigilance, but histamine also modulates other Cognitive domains such as short-term and long-term memory. A number of H 3 antagonists, including 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine hydrochloride (BF2.649), (1 R ,3 R )- N -ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]cyclobutane-1-carboxamide (PF-03654746), 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1 H -3-benzazepin-7-yl)oxy]- N -methyl-3-pyridinecarboxamide hydrochloride (GSK189254), MK-0249 (structure not yet disclosed), JNJ-17216498 (structure not yet disclosed), and ABT-288 (structure not yet disclosed), have advanced to the clinical area for the potential treatment of human Cognitive Disorders. H 3 antagonists exhibited wake-promoting effects in humans and efficacy in narcoleptic patients, indicating target engagement, but some of them were not efficacious in patients suffering from attention-deficit hyperactivity disorder and schizophrenic patients. Preclinical studies have also shown that H 3 antagonists activate intracellular signaling pathways that may improve Cognitive efficacy and disease-modifying effects in Alzheimer9s disease. Ongoing clinical studies will be able to determine the utility of H 3 antagonists for the treatment of Cognitive Disorders in humans.

  • the histamine h3 receptor an attractive target for the treatment of Cognitive Disorders
    British Journal of Pharmacology, 2008
    Co-Authors: Timothy A Esbenshade, Kaitlin E Browman, Robert S Bitner, Marina I Strakhova, Marlon D Cowart, Jorge D Brioni
    Abstract:

    The histamine H3 receptor, first described in 1983 as a histamine autoreceptor and later shown to also function as a heteroreceptor that regulates the release of other neurotransmitters, has been the focus of research by numerous laboratories as it represents an attractive drug target for a number of indications including cognition. The purpose of this review is to acquaint the reader with the current understanding of H3 receptor localization and function as a modulator of neurotransmitter release and its effects on Cognitive processes, as well as to provide an update on selected H3 antagonists in various states of preclinical and clinical advancement. Blockade of centrally localized H3 receptors by selective H3 receptor antagonists has been shown to enhance the release of neurotransmitters such as histamine, ACh, dopamine and norepinephrine, among others, which play important roles in Cognitive processes. The Cognitive-enhancing effects of H3 antagonists across multiple Cognitive domains in a wide number of preclinical cognition models also bolster confidence in this therapeutic approach for the treatment of attention deficit hyperactivity disorder, Alzheimer's disease and schizophrenia. However, although a number of clinical studies examining the efficacy of H3 receptor antagonists for a variety of Cognitive Disorders are currently underway, no clinical proof of concept for an H3 receptor antagonist has been reported to date. The discovery of effective H3 antagonists as therapeutic agents for the novel treatment of Cognitive Disorders will only be accomplished through continued research efforts that further our insights into the functions of the H3 receptor.

Marlon D Cowart - One of the best experts on this subject based on the ideXlab platform.

  • discovery of histamine h3 antagonists for the treatment of Cognitive Disorders and alzheimer s disease
    Journal of Pharmacology and Experimental Therapeutics, 2011
    Co-Authors: Jorge D Brioni, Timothy A Esbenshade, Tiffany Runyan Garrison, Scott R Bitner, Marlon D Cowart
    Abstract:

    H 3 antagonists increase the release of brain histamine, acetylcholine, noradrenaline, and dopamine, neurotransmitters that are known to modulate Cognitive processes. The ability to release brain histamine supports the effect on attention and vigilance, but histamine also modulates other Cognitive domains such as short-term and long-term memory. A number of H 3 antagonists, including 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine hydrochloride (BF2.649), (1 R ,3 R )- N -ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]cyclobutane-1-carboxamide (PF-03654746), 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1 H -3-benzazepin-7-yl)oxy]- N -methyl-3-pyridinecarboxamide hydrochloride (GSK189254), MK-0249 (structure not yet disclosed), JNJ-17216498 (structure not yet disclosed), and ABT-288 (structure not yet disclosed), have advanced to the clinical area for the potential treatment of human Cognitive Disorders. H 3 antagonists exhibited wake-promoting effects in humans and efficacy in narcoleptic patients, indicating target engagement, but some of them were not efficacious in patients suffering from attention-deficit hyperactivity disorder and schizophrenic patients. Preclinical studies have also shown that H 3 antagonists activate intracellular signaling pathways that may improve Cognitive efficacy and disease-modifying effects in Alzheimer9s disease. Ongoing clinical studies will be able to determine the utility of H 3 antagonists for the treatment of Cognitive Disorders in humans.

  • the histamine h3 receptor an attractive target for the treatment of Cognitive Disorders
    British Journal of Pharmacology, 2008
    Co-Authors: Timothy A Esbenshade, Kaitlin E Browman, Robert S Bitner, Marina I Strakhova, Marlon D Cowart, Jorge D Brioni
    Abstract:

    The histamine H3 receptor, first described in 1983 as a histamine autoreceptor and later shown to also function as a heteroreceptor that regulates the release of other neurotransmitters, has been the focus of research by numerous laboratories as it represents an attractive drug target for a number of indications including cognition. The purpose of this review is to acquaint the reader with the current understanding of H3 receptor localization and function as a modulator of neurotransmitter release and its effects on Cognitive processes, as well as to provide an update on selected H3 antagonists in various states of preclinical and clinical advancement. Blockade of centrally localized H3 receptors by selective H3 receptor antagonists has been shown to enhance the release of neurotransmitters such as histamine, ACh, dopamine and norepinephrine, among others, which play important roles in Cognitive processes. The Cognitive-enhancing effects of H3 antagonists across multiple Cognitive domains in a wide number of preclinical cognition models also bolster confidence in this therapeutic approach for the treatment of attention deficit hyperactivity disorder, Alzheimer's disease and schizophrenia. However, although a number of clinical studies examining the efficacy of H3 receptor antagonists for a variety of Cognitive Disorders are currently underway, no clinical proof of concept for an H3 receptor antagonist has been reported to date. The discovery of effective H3 antagonists as therapeutic agents for the novel treatment of Cognitive Disorders will only be accomplished through continued research efforts that further our insights into the functions of the H3 receptor.

Catherine C Price - One of the best experts on this subject based on the ideXlab platform.

  • postoperative Cognitive Disorders
    Current Opinion in Critical Care, 2011
    Co-Authors: Terri G Monk, Catherine C Price
    Abstract:

    Purpose of review The elderly are the fastest growing segment of the population and undergo 25–30% of all surgical procedures. Postoperative Cognitive problems are common in older patients following major surgery. The socioeconomic implications of these Cognitive Disorders are profound; Cognitive decline is associated with a loss of independence, a reduction in the quality of life, and death. This review will focus on the two most common Cognitive problems following surgery: postoperative delirium and postoperative Cognitive dysfunction (POCD).

Timothy A Esbenshade - One of the best experts on this subject based on the ideXlab platform.

  • discovery of histamine h3 antagonists for the treatment of Cognitive Disorders and alzheimer s disease
    Journal of Pharmacology and Experimental Therapeutics, 2011
    Co-Authors: Jorge D Brioni, Timothy A Esbenshade, Tiffany Runyan Garrison, Scott R Bitner, Marlon D Cowart
    Abstract:

    H 3 antagonists increase the release of brain histamine, acetylcholine, noradrenaline, and dopamine, neurotransmitters that are known to modulate Cognitive processes. The ability to release brain histamine supports the effect on attention and vigilance, but histamine also modulates other Cognitive domains such as short-term and long-term memory. A number of H 3 antagonists, including 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine hydrochloride (BF2.649), (1 R ,3 R )- N -ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]cyclobutane-1-carboxamide (PF-03654746), 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1 H -3-benzazepin-7-yl)oxy]- N -methyl-3-pyridinecarboxamide hydrochloride (GSK189254), MK-0249 (structure not yet disclosed), JNJ-17216498 (structure not yet disclosed), and ABT-288 (structure not yet disclosed), have advanced to the clinical area for the potential treatment of human Cognitive Disorders. H 3 antagonists exhibited wake-promoting effects in humans and efficacy in narcoleptic patients, indicating target engagement, but some of them were not efficacious in patients suffering from attention-deficit hyperactivity disorder and schizophrenic patients. Preclinical studies have also shown that H 3 antagonists activate intracellular signaling pathways that may improve Cognitive efficacy and disease-modifying effects in Alzheimer9s disease. Ongoing clinical studies will be able to determine the utility of H 3 antagonists for the treatment of Cognitive Disorders in humans.

  • the histamine h3 receptor an attractive target for the treatment of Cognitive Disorders
    British Journal of Pharmacology, 2008
    Co-Authors: Timothy A Esbenshade, Kaitlin E Browman, Robert S Bitner, Marina I Strakhova, Marlon D Cowart, Jorge D Brioni
    Abstract:

    The histamine H3 receptor, first described in 1983 as a histamine autoreceptor and later shown to also function as a heteroreceptor that regulates the release of other neurotransmitters, has been the focus of research by numerous laboratories as it represents an attractive drug target for a number of indications including cognition. The purpose of this review is to acquaint the reader with the current understanding of H3 receptor localization and function as a modulator of neurotransmitter release and its effects on Cognitive processes, as well as to provide an update on selected H3 antagonists in various states of preclinical and clinical advancement. Blockade of centrally localized H3 receptors by selective H3 receptor antagonists has been shown to enhance the release of neurotransmitters such as histamine, ACh, dopamine and norepinephrine, among others, which play important roles in Cognitive processes. The Cognitive-enhancing effects of H3 antagonists across multiple Cognitive domains in a wide number of preclinical cognition models also bolster confidence in this therapeutic approach for the treatment of attention deficit hyperactivity disorder, Alzheimer's disease and schizophrenia. However, although a number of clinical studies examining the efficacy of H3 receptor antagonists for a variety of Cognitive Disorders are currently underway, no clinical proof of concept for an H3 receptor antagonist has been reported to date. The discovery of effective H3 antagonists as therapeutic agents for the novel treatment of Cognitive Disorders will only be accomplished through continued research efforts that further our insights into the functions of the H3 receptor.

Dejan Petrovic - One of the best experts on this subject based on the ideXlab platform.

  • Analysis of Risk Factors for Development of Cognitive Disorders in Maintenance Hemodialysis Patients – Pilot Study
    Serbian Journal of Experimental and Clinical Research, 2017
    Co-Authors: Milena Jovanovic, Zeljko Todorovic, Dragan Milovanovic, Branislava Draskovic, Andreja Todorovic, Dejan Petrovic
    Abstract:

    Abstract Prevalence of Cognitive Disorders is high in maintenance hemodialysis patients. Montreal Cognitive assessment (MoCA) is used for detecting and evaluation of Cognitive disorder degree in this patient population. In examined patient population, only 5 (12.5%) of them had normal Cognitive function (MoCA ≥26). Mild Cognitive impairment (MoCA 18-26) was found in 65.9% (29) patients, while moderate Cognitive disorder (MoCA 10-17) was detected in 6 (21.6%) patients. Major Cognitive disorder wasn’t detected in examined population. Statistically significant correlation was not established between laboratory parameters and overall MoCA score. Statistically significant correlation, however, was established between MoCA item that evaluates space and time orientation and intermediate secondary hyperparathyroidism and space and time orientation and severe secondary hyperparathyroidism. Hemodynamic instability during hemodialysis and silent ischemia of the brain are increasing risk of appearance of Cognitive Disorders in maintenance hemodialysis patients.

  • Analysis of Risk Factors for Development of Cognitive Disorders in Maintenance Hemodialysis Patients - Pilot Study
    Serbian Journal of Experimental and Clinical Research, 2016
    Co-Authors: Milena Jovanovic, Zeljko Todorovic, Dragan Milovanovic, Branislava Draskovic, Andreja Todorovic, Dejan Petrovic
    Abstract:

    Abstract Prevalence of Cognitive Disorders is high in maintenance hemodialysis patients. Montreal Cognitive assessment (MoCA) is used for detecting and evaluation of Cognitive disorder degree in this patient population. In examined patient population, only 5 (12.5%) of them had normal Cognitive function (MoCA ≥26). Mild Cognitive impairment (MoCA 18-26) was found in 65.9% (29) patients, while moderate Cognitive disorder (MoCA 10-17) was detected in 6 (21.6%) patients. Major Cognitive disorder wasn’t detected in examined population. Statistically signifi cant correlation was not established between laboratory parameters and overall MoCA score. Statistically signifi cant correlation, however, was established between MoCA item that evaluates space and time orientation and intermediate secondary hyperparathyroidism and space and time orientation and severe secondary hyperparathyroidism. Hemodynamic instability during hemodialysis and silent ischemia of the brain are increasing risk of appearance of Cognitive Disorders in maintenance hemodialysis patients.